Equity Field Notes from temporal sources

[DanWebzster]

ATXI is a Fortress Biomedical company trying to get IV Tramadol approved as a post-surgical pain medication.

Presently, 80% of post-surgical patients get conventional narcotics for pain management.

Studies have shown that 1 out of 16 of these patients are at risk of Opioid addiction.

IV Tramadol is a Schedule IV drug with a far more benign risk of leading to Opioid addiction than narcotics yet more effective than IV N-SAIDs or IV Tylenol.

Ph3 results are due mid/19 and an NDA would likely be filed before EOY/19.

Cash runway could be stretched into Q1/19.

Additional capital will be required before pivotal Ph3 data is due.